No câncer, o aumento da expressão das enzimas indolamina 2,3-dioxigenase 1 (IDO1) e triptofano 2,3-dioxigenase (TDO), que convertem o triptofano (Trp) em quinurenina (QUIN), tem sido associado ao mecanismo de imuno escape tumoral e inibidores destas enzimas têm sido considerados como imunoadjuvantes na terapia antitumoral. O mais conhecido deles é o 1-metil-triptofano (1-MT), um inibidor competitivo da IDO e alvo de estudos clínicos. O 1-MT é encontrado nas formas enantioméricas D- e L- e embora o enantiômero 1-L-MT seja mais eficiente na inibição da IDO1 (a isoforma mais ativa em tumores), é o 1-D-MT o enantiômero mais eficiente na redução experimental de tumores. Esse dado sugere que o 1-MT pode ter ações adicionais à inibição da IDO. Neste estudo avaliamos os efeitos diretos dos estereoisomeros, 1-D-MT, 1-L-MT, 1-DL-MT, sobre melanomas humanos e também do composto 680C91 (um inibidor de TDO). Proliferação, migração e invasão são os ensaios usuais in vitro para avaliar como um determinado composto afetaria a progressão tumoral. Observamos que todos os compostos testados possuem algum efeito direto sobre pelo menos um desses parâmetros, sendo que esse efeito varia de acordo com a linhagem. Logo, todos eles possuem ação direta sobre a célula tumoral que deve contribuir com a atividade antineoplásica. Também analisamos os efeitos destes compostos sobre a ação tumoricida de células mononucleares de sangue periférico humano (PBMC). Em co-culturas, observamos que o 1-MT foi capaz de potencializar a atividade tumoricida de PBMC\'s e levou à diminuição da produção de IFN-γ e TNF-α e aumento de IL-10. Essas alterações não cursam com a inibição da produção de QUIN, o que nos faz pensar que esta ação de 1-MT sobre IFN-γ ocorre independente da enzima IDO e que parte dos efeitos antitumorais da 1-MT seja consequência de sua ação sobre a liberação destas citocinas. 1-MT também levou a modificações na concentração de outros metabólitos do Trp. Por fim, a co-cultura por si só aumentou o consumo de ácido xanturênico (XA) e aumentou a produção de ácido quinurênico (KA). Esse resultado parece significativo para a imunologia de tumores dado os efeitos biológicos destes compostos. / In cancer, the increased expression of the enzymes indolamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), that convert tryptophan (Trp) to kynurenine (KYN), has been associated with the mechanism of immune escape of tumoral cells and inhibitors of these enzymes have been considered as immuno-adjuvants in antitumor therapy. The most known is the 1-methyl-tryptophan (1-MT), a competitive inhibitor of IDO and a target in clinical trials. 1-MT is found in the enantiomeric forms D- and L- and although 1-L-MT is more efficient to inhibit IDO1 (the isoform more active in tumors), 1-D-MT is more efficient in experimental models. This fact suggests that 1-MT may have additional actions beyond IDO inhibition. In this study, we evaluated the direct effects of 1-D-MT, 1-L-MT and 1-DL-MT on human melanomas. We also tested the effects of the compound 680C91 (an inhibitor of TDO). Proliferation, migration and invasion are the usual in vitro tests to evaluate how a specific compound affects tumor progression. We observed that all of the tested compounds have some direct effect on at least one of these parameters depending on the cell lineage. Therefore, direct effects on proliferation, migration and invasion must compose the antineoplastic activity of these compounds. In co-cultures, we observed that 1-MT was able to potentiate the tumoricidal activity of peripheral blood mononuclear cells (PBMC) and led to a decreased production of IFN-γ and TNF-α, and an increase in IL-10. These changes were not linked with the inhibition of KYN production, and led us to consider that the effect of 1-MT on cytokine production occurs independently of the enzyme IDO and is part of its antitumor effects. 1-MT also led to changes in the concentration of other Trp metabolites. Finally, the co-culture by itself led to an increased consumption of xanthurenic acid (XA) and increased production of kynurenic acid (KA). This result seems significant to the immunology of tumors given the biological effects of these compounds.

La surinfection par HDV/ HBV est la forme la plus grave d'hépatite virale chronique et affecte entre 15-20 millions de patients au niveau mondial. HDV n'est pas susceptible aux traitements anti-HBV et le taux de réponse à l'IFNα est <25%. Malgré une progression plus rapide de la maladie hépatique, la majorité des patients présente une suppression de la réplication du HBV. Les détails des interactions entre HDV, HBV et le système immunitaire inné des cellules infectées restent inconnus. Les objectifs de ces travaux de thèse ont été: i) l'étude de l'infection par HDV et son interaction avec la réponse innée cellulaire; ii) l'identification de nouvelles stratégies thérapeutiques anti-HDV; iii) l'exploration de l'interaction entre HDV et HBV. L'approche expérimentale a été basée sur l'infection de cellules dHepaRG, capables d´entretenir des cycles réplicatifs complets de HBV et HDV et ayant une réponse immunitaire innée physiologique. Nous avons observé que: i) l'infection par HDV est associée à un réplication forte dans un nombre limité de cellules, et à une induction de l'expression des ISGs; ii) le traitement des cellules infectées par HDV avec de l'IFNα ne conduit pas à une induction accrue des ISGs et a une faible activité antivirale. Quelques agonistes de PRR, notamment activant la voie NF-kB, induisent une forte diminution de la réplication de HDV; iii) malgré le faible nombre de cellules infectées, HDV et ses protéines induisent une diminution de la réplication de HBV. Ces travaux ouvrent des perspectives importantes concernant la caractérisation de la pathogénèse de l'hépatite delta et l'identification de nouvelles stratégies thérapeutiques immuno modulatrices / HDV/HBV superinfection is the most aggressive form of chronic viral hepatitis and is estimated to affect 15-20 million patients worldwide. HDV is not susceptible to available direct anti-HBV drugs and sustained response to IFNα therapy occurs in less than 1/4 of patients. Despite the faster progression of liver disease, most HDV/ HBV infected patients present a suppression of HBV replication. The details of the interactions between HDV, HBV and the host cell innate immune response remain largely unexplored and research efforts have been limited by the lack of infection models. The aims of this thesis work were: i) to study HDV infection and the interplay with the host innate immune response; ii) to identify novel therapeutic strategies for the inhibition of HDV; iii) to further explore HDV/ HBV interference. The experimental strategy was based on infection of dHepaRG cells, which are known to be permissive to both HBV and HDV full replicative cycles and to present physiological innate immune responses. We observed that: i) HDV infection is associated with a strong, yet transient replication, a potent induction of the expression of ISGs; ii) IFN-α treatment of HDVinfected cells does not induce a further increase of ISG expression and has a modest antiviral activity. Conversely, some PRR agonists, in particular those inducing the NFkB pathway, induce a strong decline in HDV replication; iii) despite the low number of coinfected cells, HDV as well as its encoded proteins exert a repressive effect on HBV replication. Our work opens an array of perspectives on the pathogenesis of hepatitis delta and the identification of novel immune modulatory therapeutic strategies

Le cancer du sein est une maladie impactant le système immunitaire dont le rôle évolue au cours de la tumorigénèse, allant de la détection et l'élimination des cellules transformées (immunosurveillance) à la promotion du développement tumoral (immunosubversion). Les efforts déployés pour définir de nouvelles stratégies thérapeutiques ont révélé que rétablir l'immunité anti-tumorale chez les patientes permettrait d'améliorer leur pronostic. Durant ma thèse, nous avons mis en évidence l'existence de signaux activateurs et inhibateurs des pDC dans les cancers du sein, qui confèrent aux pDC un rôle dans l'immunosurveillance et dans l'échappement immunitaire du cancer du sein respectivement. Nous avons ainsi montré que le TGF-beta et le TNF-alpha sont impliqués dans l'inhibition fonctionnelle des TApDC en réprimant l'expression et l'activation d'IRF-7. Dans un second temps, nous avons montré i) la présence de complexes [ADN-LL37] produits par les neutrophiles dans les tumeurs et capables d'induire la production d'IFN-alpha par les pDC, ii) l'expression des gènes associés aux IFN-I dans les tumeurs de sein et iii) un rôle majeur de la voie des IFN-I dans l'immunosurveillance des tumeurs mammaires chez la souris. De plus, des données préliminaires chez la souris suggèrent que les pDC participent à l'immunosurveillance anti-tumorale in vivo. Les travaux présentés dans ce manuscrit apportent de nouvelles données sur le rôle des pDC dans l'immunosurveillance des cancers du sein et ouvrent sur de nouvelles stratégies d'immunothérapie anti-tumorale ciblant les pDC / Breast cancer are disease impacting immune system whose play role during tumorigenesis, to detect and eliminate malign cells (immunosurveillance) or promote tumoral development (immunosubversion). Efforts to define new therapeutic strategies revealed that restoring anti-tumor immunity in patients would improve their prognosis. During my thesis, first, we demonstrated the existence of stimulatory and inhibitory signals of pDCs in the breast, which give the pDCs a role in immunosurveillance and immune escape of breast cancer, respectively. We showed that TGF-beta and TNF-alpha are involved in the functional inhibition of TApDC repressing IRF-7 expression and activation. Secondly, we showed i) the presence of [DNA LL37] complex produced by neutrophils in tumors that can induce the production of IFN-alpha by pDCs, ii) the expression of type I IFN associated genes in breast tumors and iii) a major role of IFN-I pathway in immunosurveillance of mammary tumors in mice. In addition, in mice, preliminary data suggest that pDC could play a role in anti-tumor immunosurveillance in vivo. The work presented in this thesis provide new data on the role of pDCs in immunosurveillance of breast cancers, and open new anti-tumor immunotherapy strategies targeting pDCs

Lors d'une infection virale, l'hôte déclenche une réponse rapide, la rémonse immunitaire innée, dont l'interféron (IFN) de type I est la cytokine centrale. Des motifs moléculaires associés aux micro-organismes (MAMP) sont déteectés par de nombreux récepteurs dédiés, dont les récepteurs cytoplasmiques de type RIG-I (RLR) identifiés à partir de 2004. Les RLR, au nombre de trois, RIG-I, MAD5 et LGP2, sont les ARN-hélicases composées de deux ou trois types de domaines : deux domaines CARD, resposables du recrutement de la cascade de signalisation, un domaine C-terminal CTD, site de liaison initial de l'ARN viral, et le domaine central hélicase, site secondaire de liaison àl'ARN et possédant également une activité enzymatiques ATP-dépendante. RIG-I est impliqué dans la détection de plusieurs virus dont ceux de l'ordre des mononegavirales (virus de la rage, de la rougeole, Ebola). Ce récepteur reconnait des ARN viraux possédant une région double brin adjacente à une extrémité 5'-triphosphate. Les nombreuses études menées n'ont cepnedant pas encore permis de dégager un mécanisme complet et cohérent de l'activation de RIG-I. Notre objectif était donc d'apporter des réponses molécualires quant au mécanismes d'activation de RIG-I. Dans un premier temps, l'élucidation de la structure de la protéine entière RIG-I de canard, par l'équipe de Stephen Cusack, leur a permis d'identifier une conformation auto-réprimée de la protéine. En l'absence d'ARN le domaine CARD2 interagit avec le sous domaine Hel2i du domaine hélicase. Nous avons apporté une preuve fonctionelle de cette observation. Les mutations F540 A/D, du résidu situé dans le sous domaine Hel2i, inhibent l'interaction CARD2-Hel2i et produisent des mutant constituvement actifs. A l'opposé, les mutations correspondantes dans le domaine CARD2 rendent RIG-I inactif. L'interaction CARD2-Hel2i semble donc impliquer une double auto-répression via (i) le masquage du site de liaison à l'ARN du sous-domaine Hel2i, et (ii) le masquage de résidus du domaine CARD2 impliqués dans le recrutement d'intermédiaires requis pour la transduction du signal. Par ailleurs, l'étude de mutants impliqués dans la liaison et l'hydrolyse de l'ATP nous a permis de proposer un nouveau rôle régulateur pour cette activité enzymatique. Dans un deuxième temsp, l'étude de la nécessité de l'oligomérisation de RIG-I pour l'activation de la réponse IFN a été menée. Eva Kowalinski, en thèse dans l'équipe de Stephen Cusack, n'observe la formation de dimères de RIG-I, in vitro, qu'en présence d'un ARN synthétique possédant deux extrémités 5'-triphosphate. Nous avons complété cette observation avec des analyse montrant que des ARN synthéttiques leader incapables d'induire la dimérisation de RIG-I in viro, activent néanmoins ce récepteur in cellula. Par ailleurs, nim'utilisation de la technique de co-immunoprécipitation, ni celle du test de complémentation basé sur la luciférase Gaussia, avec ou sans activiation par un ARN ou une infection virale, n'ont permis d'observer d'oligomérisation de RIG-I. L'auto-association de RIG-I ne semble donc pas être indispensable pour son activation. / Vertebrate are permanently threatened by infections that they manage to counteract using a dedicated system. The innate immunity allows a rapid response against viral infection, mainly through the type I interferon (IFN) production. Dedicated receptors detect microbe-associated molecular patterns (MAMPs), and among them the RIG-likereceptors (RLRs), RIG-I, MDA5 and LGP2, can sense viral RNA into the cytoplasm. RLRs are compossed of two or three different domains : two N-terminal CARDs domains are resposible for signal transduction, a C-terminal domains is the first RNA binding site, and a central helicase domainis the second RNA binding site and possesses an ATP-dependent activity. RIG-I is important for sensing of several mononegavirales, such as rabies, measle and Ebola viruses, and recongnized 5'-triphosphorylated double stranded RNA. Despite intensive studies, a full and comprehensive model of the mechanismof RIG-I activation is still lacking. Our aim was to clarify the first molecular steps of RIG-I activation. First, Stephen Cusack's team elucidated the structure of the full lenght duck RIG-I protein and identified the principle of RIG-I auto-repressed conformation. In absence of ligand RNA, CARD2 domain interacts with Hel2i subdomain of helicase domain. We confirmed this conformation with functional evidence. Mutaions F540A/D, in Hel2i subdomain, inhibits CARD2:Hel2i interaction and renders RIG-I constitutively active. In contrast, the corresponding mutations in the Hel2i contacting site of CARD2 domain produce inactive mutants. Thus CARDS;Hel2i interactio induces an auto-repressed state through a deual masking of both Hel2i RNA binding site and CARD2 residus necessary for signal transduction. Moreover, study of mutants involved in ATP binding and hydrolysis reealed a portential unsuspected regulatory role for the ATP-dependent enzymatic activity of RIG-I. Second, we studied the necessity of RIG-I oligomerization for RIG-I activation. Eva Kowalinski, PhD student in Stephen Cusack's team, observed RIG-I dimers in vitro, only in presence of synthetic RNA with two 5'triphosphorylated ends. We complete this observation with functional assays showing that synthetic leader RNA incapable to induce RIG-I oligomerization in vitro, did activate RIG-I in cellula. Moreover, we did not observe RIG-I oligomerization using either co-immunoprecipitation or Gaussia Luciferase-based-protein complementation assay, after activation with cognate RNA or viral infection. Altogether our results indicate that the self-oligomerization og RIG-I is either dispensable or very transient for signal transduction.

Toxoplasma gondii ist ein weltweit verbreiteter Parasit. In Europa ernährt sich der Endwirt (Katzen) hauptsächlich von kleinen Säugetieren wie Myodes glareolus und Microtus spp. (Wühlmäusen) und Apodemus spp., seltener von Mus spp. Erstere zeigen gegenüber Mus spp. erhöhte Prävalenzen von T. gondii und überleben diese eher als Mus spp. Daher wird vermutet, dass Wühlmäusen und Apodemus spp. eine größere Rolle als Zwischenwirte besitzen, als Mus spp. Der Schutz wird auf das IFN-γ-induzierte IRGb2-b1 zurückgeführt, die den zentralen parasitären Virulenzfaktor ROP5 inhibiert. Daher liegt der Fokus meiner Arbeit auf der protektiven Rolle von IRGb2-b1 bei der Infektion mit T. gondii in Wühlmäusen und Apodemus spp. Mit dieser Arbeit trage ich nützliche Werkzeuge zur Erforschung von Wühlmäusen bei, wie ein rekombinantes M. glareolus IFN-γ Zytokin und neuartige Zellsysteme. Alle untersuchten Wühlmaus-Systeme besaßen einen Phänotyp bei Infektion mit in vivo Resistenz beschrieben wurde: einem IFN-γ-vermittelten Reduktion der Parasitenbürde (mit Wirtszelltod für Typ I Parasiten, ohne für Typ II). Darüber hinaus bestätigen vorläufige Resultate aus Wühlmäusen und Apodemus spp. in Deutschland hohe genetische Vielfalt der IRGb2 Untereinheit zeigen, insbesondere an der vermuteten Grenzfläche zum ROP5, was auf eine Rolle dieses Proteins bei der Infektion hindeutet. Um die Funktion der IRGb2-b1 Proteine zu untersuchen, habe ich ein Zellkultur System, entwickelt, welches erlaubt wild-derived Gene stabil zu exprimieren. Dieses Setup gestattet es, die Auswirkungen von Polymorphismen in Irg Genen bei der Infektion mit T. gondii zu evaluieren. Insgesamt habe ich Werkzeuge erarbeitet, um den Ansatz der Öko-Immunologie in eine Labor-Umwelt zu bringen, wodurch die molekulare Untersuchung ökologisch relevanter Arten möglich wird. Durch Anwendung dieser Werkzeuge stütze ich die Hypothese, dass nicht-Mus Nagetiere, insbesondere M. glareolus, ein bedeutendes Reservoir für T. gondii darstellen. / Toxoplasma gondii is an ubiquitous parasite grouped in three main clonal lineages, type I-III. In Europe, felids, definitive hosts for the parasite, mostly prey on small mammals of Myodes glareolus and Microtus spp. (voles), and Apodemus spp., rather than Mus spp. Voles and Apodemus spp. also display higher T. gondii prevalence and survive infection to a larger extent than Mus spp., although tolerant Mus subspecies exist. This suggests that voles and Apodemus spp. are more relevant intermediate hosts than Mus spp.. Resistance to infection relies on the IFN-γ-induced IRGb2-b1, which inhibits the major parasite virulence factor ROP5. Thus, this work focuses on the protective role of IRGb2-b1 during T. gondii infection in voles and Apodemus spp. With this project I contribute with valuable tools for research on voles, such as the supply of the recombinant M. glareolus IFN-γ cytokine and novel cell systems. All vole systems show a phenotype to type I infection which is associated with in vivo resistance in Mus spp: IFN-γ-mediated host cell death and a decrease in parasite burden. The latter without cell death was observed for type II parasites, suggesting novel protective mechanisms. Further, preliminary results from voles and Apodemus spp. in Germany confirm the expected high diversity in the IRGb2-like subunit, especially at the putative interface with ROP5, which suggests a role of the protein during infection. To assess the role of IRGb2-b1-like in this phenotype, I developed a system which allows establishment of cell lines stably expressing wild-derived Irg-like genes. This setup allows evaluation of the effect of polymorphisms of Irg-like genes during infection. Taken together, I have provided tools to bring eco-immunology into a lab setting to perform molecular investigations of ecologically relevant species. Using these tools, I offer support for the hypothesis that non-Mus rodents, especially M. glareolus, constitutes a relevant T. gondii reservoir in Germany.

Le virus Influenza de type A (IAV) est un agent pathogène hypervariable responsable d’une infection respiratoire aiguë appelée la grippe. L’hyper-variabilité de ce virus IAV lui permet d’être résistant aux traitements antiviraux et est responsable de l’apparition des épidémies de grippe saisonnières. Il est donc essentiel d’établir de nouveaux traitements curatifs « à spectre large » insensibles aux variations du virus de la grippe. Les nanoparticules d’argent (NPs-Ag) sont les nanomatériaux métalliques les plus présents dans le secteur de la santé. En effet, leurs propriétés physico-chimiques leur confèrent de nombreuses capacités telles que la modulation des réponses immunitaires au niveau du poumon et des effets antimicrobiens. Quelques études ont démontré le potentiel anti-IAV des NPs-Ag lorsqu’elles sont placées directement en contact avec le virus IAV. Cependant, aucune de ces études ne porte sur les effets des NPs-Ag dans un contexte physiologique constitué d’une infection grippale suivie d’un traitement. D’autre part, au jour d’aujourd’hui, on ignore les mécanismes d’action mis en place par ces NPs-Ag et les effets induits par l’interaction de ces NPs-Ag avec le système immunitaire dans le contexte d’une infection par l’IAV. Dans ce travail de thèse, l’objectif est d’identifier les mécanismes d’action mis en place par les NPs-Ag au cours de l’infection par le virus IAV et également d’identifier si ces NPs-Ag pourraient être utilisées comme traitement curatif.Dans ce manuscrit de thèse, nous avons pu identifier, dans les cellules épithéliales pulmonaires, un nouveau mécanisme de modulation des NPs-Ag sur la réponse anti-IAV précoce médiée, entre autres, par la sécrétion de la chimiokine CCL5 et de l’IFN-. En effet, les NPs-Ag ciblent spécifiquement la voie de signalisation RIG-I-MAVS-IRFs, activée suite à l’infection par l’IAV et qui est liée à la mitochondrie. Ces NPs-Ag ciblent également en parallèle, à la fois le réseau mitochondrial et le flux autophagique. L’ensemble de ces effets conduit à une redistribution des facteurs de régulation des IFNs (IRFs), les empêchant potentiellement d’interagir avec d’autres facteurs de la voie de signalisation RIG-I/MAVS, ce qui pourrait expliquer l’inhibition de la sécrétion de CCL5 et de l’IFN-b, induite par le virus influenza de type A, par les nanoparticules d’argent. / The Influenza A virus (IAV) is a hyper-variable pathogen causing acute respiratory infection known as Flu. Its hyper-variability allows it to be resistant to antiviral treatment. It is therefore essential to establish new curative "broad spectrum" treatments. Silver nanoparticles (NPs-Ag) are the most metallic nanomaterials present in the health sector and are potent microbicidal agents with major concerns about their use on humans because of their toxicity. Some studies have shown the antiviral effect of NPs-Ag against IAV, but not in a physiological context of Flu. Moreover, the antiviral and immunomodulation mechanisms of NPs-Ag during infection by IAV is still unclear. Here, we show that intra-tracheal administration of AgNPs to influenza infected mice or treatment of human lung epithelial cells with AgNPs resulted in exacerbated inflammation, reduced viral clearance and enhanced mortality associated to different regulation of KC (pro-inflammatory cytokine functionally homologue to human IL-8) and CCL-5 (interferon-related cytokine) in the lung. In this PhD thesis, we identified in lung epithelial cells, a new mechanism explaining dampening of mitochondrial antiviral immunity by AgNPs through alteration of the mitochondrial network leading to redistribution of IFNs regulatory factors 7, which prevents nuclear translocation of these factors. Finally, AgNPs increased LC3 positive vesicles and p62 expression, indicating that AgNPs modify the autophagy flux in lung epithelial cells. Thus, the NPs-Ag Ag inhibited the early anti-IAV response by specifically targeting the RIG-I/MAVS/IRFs signaling pathway resulting in down- regulation of CCL-5 and IFN-ß expression induced by IAV.

Swine influenza viruses (SIV) are a common and an important cause of respiratory disease in pigs. Pigs can serve as mixing vessels for the evolution of reassortment viruses containing both avian and human signatures, which have the potential to cause pandemics. NS1 protein of influenza A viruses is a major antagonist of host defence and it regulates multiple functions during infection by interacting with a variety of host proteins. Therefore, it is important to study swine viruses and NS1-interacting host factors in order to understand the mechanisms by which NS1 regulates virus replication and exerts its host defense functions. Influenza A viruses enter the host through the respiratory tract and infect epithelial cells in the respiratory tract, which form the primary sites of virus replication in the host. Thus, studying SIV infection in primary swine respiratory epithelial cells (SRECs) would resemble conditions similar to natural infection. The objectives of this study were to identify NS1-interacting host factors in the virus-infected SRECs and to understand the physiological role of at least one of the factors in influenza virus infection. The approaches to meet this objective were to generate a recombinant SIV carrying a Strep-tag in the NS1 protein, infect SRECs with the Strep-tag virus, purify NS1-interacting host protein complex from the infected cells by pull-down using strep-tactin resin and then study the physiological role of one of the NS1-interacting partners during influenza infection. Using a reverse-genetics strategy, a recombinant virus carrying the Strep-tag NS1 was successfully rescued and the SRECs were infected with this recombinant virus. The Strep-tag in the NS1 protein facilitated the isolation of an intact NS1-interacting protein complex and the proteins present in the complex were identified by liquid chromatography-tandem mass spectrometry. The identified proteins were grouped to enrich for different functions using bioinformatics. This gave an insight into the different functions that NS1 may regulate during infection and the potential host partners involved in these functions. Among the host proteins identified as potential interaction partners, RNA helicases were particularly of interest to study. Influenza being an RNA virus, RNA helicases could have important functions in the virus life cycle. Among the identified RNA helicases, DDX3 has been shown to regulate IFNβ induction and affect the life cycle of a number of viruses. However, its function in influenza A virus life cycle has not been studied. Hence, this study explored whether DDX3 has any role in the influenza A virus life cycle. Immunoprecipitation studies revealed viral proteins NP and NS1 as direct interaction partners with DDX3. DDX3 is a known component of stress granules (SGs) and influenza A virus lacking the NS1 gene is reported to induce SG formation. Therefore, the role of DDX3 in SG formation, induced by PR8 influenza A virus lacking NS1 (PR8 del NS1) was explored. The results from this study showed that DDX3 co-localized with NP in SGs indicating that DDX3 may interact with NP in the SGs. NS1 protein was found to inhibit virus-induced SGs and DDX3 downregulation impaired virus-induced SG formation. The contribution of the different domains of DDX3 to viral protein interaction and virus-induced SG formation was also studied. While DDX3 helicase domain did not interact with NS1 and NP, it was essential for DDX3 localization in virus induced SGs. Moreover, DDX3 downregulation resulted in the increased replication of PR8 del NS1virus, accompanied by an impairment of SG induction in infected cells. Since DDX3 is reported to regulate IFNβ induction, the role of DDX3 in influenza A virus induced IFNβ induction was also examined. Using small molecule inhibitors and siRNA-mediated gene knockdown, the RIG-I pathway was identified as the major contributor of influenza induced IFNβ induction in newborn porcine tracheal epithelial (NPTr) cells. DDX3 downregulation and overexpression also showed that DDX3 has an inhibitory effect on IFNβ expression induced by both influenza infection and low molecular weight (LMW) poly I:C treatment, which is also a RIG-I ligand. RNA competition assay to identify the mechanism of DDX3-mediated inhibition, showed that RIG-I binding affinity to its ligands LMW poly I:C and influenza viral RNA (vRNA) is much higher than that of DDX3. Furthermore, DDX3 downregulation enhanced titers of the PR8 del NS1 virus, while it did not affect the titers of the wild-type strains of PR8 and SIV/SK viruses. Overall, the results show that DDX3 has an antiviral role and the SG regulatory function of DDX3 has a profound effect on virus replication than the IFNβ regulatory function.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Differential Display technique was used for gene profiling in trnasformed human umbilical vein endothelial cell line (ECV 304) and primary human umbilical vein endothelial cells (HUVECs) to study the cellular response to viral infection. After screening the mRNA from uninfected and infected HUVECs and ECV 304 cells with 16 different random primers we identified 8 gene targets. These genes included the human inhibitor of apoptosis-1 (h-IAP1), 2'-5' oligoadenylate synthetase (2'-5' OAS), 2'-5' oligoadenylate synthetase-like (2'-5' OAS-like), Galectin-9 (Gal-9), MxA, Mx1, Regulator of g-protein signaling (RGS2) and endothelial and smooth muscle cell-derived neuropilin-like protein (ESDN). We found that HUVECs were a better model to study gene expression dureing dengue 2 virus infection but not the transformed cell line, ECV 304. Of the 41 primer combinations utilized in ECV 304 cells detected only one upregulated gene, h-IAP1 and 8 out of the 16 primer combinations tried for HUVECs. We hypothesize the activation of two novel signaling pathways (Tumor necrosis factor- alpha (TNF-alpha), Interleukin1-beta (IL1-beta) in endothelial cells during D2V infection. ALso, our data detected genes that are activated in the Type-I IFN (IFN alpha/beta) signaling pathway during dengue 2 virus infection in HUVEC.

The adenosine deaminase acting on RNA (ADAR) enzymes catalyse the hydrolytic deamination of adenosine (A) to inosine (I) in double stranded (ds) RNA. Mutations in ADAR1 underlie the autoimmune disorder Aicardi Goutiѐres syndrome (AGS). Patients with AGS display heightened levels of type I interferon (IFN) and IFN stimulated genes (ISGs). The first aim of my thesis was to determine whether the mutations found in the human ADAR1 gene affected RNA editing. I found that the ADAR1 mutants identified in the AGS patients have reduced editing activity. Interestingly, the mutations have a greater effect on the IFN-inducible cytoplasmic isoform, ADAR1p150 than on the constitutive ADAR1p110 isoform. These results imply that A-to-I editing plays a role in regulating the type I IFN response. The Adar1 null mouse dies by E12.5 with a type I IFN signature similar to that observed in the AGS patients. The second aim of my thesis was to characterize the immune signalling pathway aberrantly activated in the absence of Adar1. A colleague in our research group rescued the Adar1 null mouse to birth by blocking the cellular response to cytoplasmic dsRNA by generating a double mutant with the mitochondrial antiviral signalling adaptor, Mavs. In the Adar1-/-; Mavs-/- mutant I found that the aberrant immune response is rescued at E11.5. This indicates that MAVS is the downstream adaptor in the aberrant immune response that underlies the embryonic lethality in the Adar1-/- mouse. The third aim of my thesis was to determine if the lack of inosine modification within cellular RNA was triggering the aberrant immune response in the Adar1-/- mouse. To study this, Adar1-/-; p53 -/- mouse embryonic fibroblasts (MEFs) were generated. By reintroducing various ADAR isoforms into the Adar1-/-; p53 -/- MEFs I found that to rescue the aberrant immune response requires both catalytic activity and the location of an ADAR protein within the cytoplasm. Moreover, I demonstrated that transfecting inosine-containing dsRNA oligonucleotides into Adar1-/-; p53 -/- MEFs suppresses the aberrant immune response. Overall my results suggest that A-to-I editing by ADAR1 is an essential RNA modification that is required by the cell to distinguish between ‘self’ and ‘non-self’ RNA. Editing of cellular RNAs prevents an autoimmune response whereas editing of viral RNA may act to suppress a heightened antiviral immune response and prevent long-term damage to the cell.